Use access key #2 to skip to page content.
$49.39 -1.11 (-2.20%)
10/6/2008 4:00 PM

Biogen Idec, Inc. (BIIB)

CAPS Rating:
****

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

View All Commentary (BIIB)

Recs

1

Avatar Actionman2go (< 20) Submitted: 4/13/07 9:40 AM : Outperform Start Price: $45.00 BIIB Score: 37.44

A biopharmaceutical company "engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases." The company is developing products to treat various autoimmune diseases (such as psoriasis, rheumatoid arthritis and lupus).

Report this Post Replies: 0 | Reply

Featured Broker Partners